Pfizer announces successful CAPiTA trial of Prevenar 13
Pfizer's CAPiTA study was conducted to evaluate the efficacy of Prevenar 13, a 13-valent, adsorbed, polysaccharide conjugate vaccine against the pneumococcal virus and recruited approximately 85,000 participants 65 years of age and older.
The study was conducted primarily to test the efficacy of Prevenar 13 against vaccine-type, community-acquired pneumonia during the first episode. Secondary goals of the study were to evaluate the efficacy of the vaccine against a non-bacteremic/non-invasive vaccine-type CAP during the first episode and against vaccine-type invasive pneumococcal disease.
"We are pleased with the outcome of the CAPiTA study, which demonstrated that Prevenar 13 can prevent vaccine-type pneumococcal community-acquired pneumonia in adults," Pfizer Senior Vice President of Vaccine Clinical Research Dr. William Gruber said.
Pfizer said its trial was successful and will present detailed data of the study at the 9th International Symposium on Pneumococci and Pneumococcal Diseases on March 12, 2014.
"Pfizer looks forward to sharing the CAPiTA data with U.S. and worldwide regulatory authorities, and vaccine technical committees, to help inform decisions regarding potential Prevenar 13 label and recommendation updates," Pfizer Senior Vice President of Vaccine Research and Development Dr. Emilio A. Emini said.